Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Liabilities and Shareholders Equity (2021 - 2025)

Historic Liabilities and Shareholders Equity for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $109.8 million.

  • Aligos Therapeutics' Liabilities and Shareholders Equity rose 2413.09% to $109.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $465.3 million, marking a year-over-year decrease of 239.22%. This contributed to the annual value of $70.1 million for FY2024, which is 5374.16% down from last year.
  • Per Aligos Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $109.8 million for Q3 2025, which was up 2413.09% from $134.7 million recorded in Q2 2025.
  • Aligos Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $263.1 million during Q3 2021, with a 5-year trough of $70.1 million in Q4 2024.
  • Its 5-year average for Liabilities and Shareholders Equity is $152.9 million, with a median of $146.7 million in 2022.
  • Per our database at Business Quant, Aligos Therapeutics' Liabilities and Shareholders Equity tumbled by 5374.16% in 2024 and then soared by 2413.09% in 2025.
  • Over the past 5 years, Aligos Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $235.4 million in 2021, then tumbled by 37.68% to $146.7 million in 2022, then grew by 3.3% to $151.5 million in 2023, then crashed by 53.74% to $70.1 million in 2024, then soared by 56.6% to $109.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $109.8 million for Q3 2025, versus $134.7 million for Q2 2025 and $150.7 million for Q1 2025.